Legislative Activity

The "Maintaining Investments in New Innovation Act" amends the Social Security Act's definition of "qualifying single source drug" to include advanced drugs using genetically targeted technology. This update applies to drugs that can modify gene function, potentially impacting drug pricing and access regulations under the Act.

The "Sarah Keys Evans Congressional Gold Medal Act" authorizes the presentation of a Congressional Gold Medal to Sarah Keys Evans, a civil rights pioneer, for her courageous refusal to give up her seat on an interstate bus, which led to the landmark ICC ruling that outlawed segregation on interstate buses. The Act directs the Secretary of the Treasury to create the gold medal and authorizes the creation and sale of bronze duplicates.

The Honor and Remember Flag Recognition Act designates the Honor and Remember Flag as the official national symbol recognizing members of the U.S. Armed Forces who die in the line of duty. It mandates the flag's display at various federal locations on specific holidays, including Armed Forces Day, Memorial Day, and Veterans Day. The bill requires relevant departments to establish regulations for flag display and directs the General Services Administration to procure and distribute the flags.

The Veterans Jobs Opportunity Act establishes a tax credit for veteran-owned small businesses in underserved communities, providing a credit of 15% of qualified start-up expenditures up to $50,000. It defines eligibility criteria, including business size, veteran ownership, and location in areas like HUBZones or low-income communities. The bill also mandates periodic evaluations of the credit's effectiveness.

The "Reducing Drug Prices for Seniors Act" mandates that Medicare Part D drug coinsurance be calculated based on a drug's actual acquisition cost rather than the wholesale price, beginning January 1, 2026. This change affects costs incurred between the annual deductible and the out-of-pocket threshold. The actual acquisition cost is defined as the negotiated price less any manufacturer concessions.

The Modern Authentication of Pharmaceuticals Act of 2025 aims to enhance the security of the pharmaceutical supply chain by requiring a physical chemical identifier on each dose of solid oral controlled substances manufactured five years after the law's enactment. It revises the definition of "product identifier" to include either a standardized graphic with specific information or a physical chemical identifier. The act also updates the definition of "verification" to include confirming product authenticity using the physical chemical identifier.